ARAVIND PAI: Open Payments
NPI 1629076088 · REDDING, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,595 in 48 payments from 11 companies in 2025. Trend: 2023 $357 · 2024 $980 · 2025 $1,595
Food & beverage: $1,595
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $413 |
| Janssen Pharmaceuticals, Inc | 11 | $269 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $236 |
| Teva Pharmaceuticals USA, Inc. | 6 | $229 |
| ABBVIE INC. | 4 | $181 |
| Axsome Therapeutics, Inc. | 5 | $131 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
Products named: INGREZZA, SPRAVATO, CAPLYTA, VRAYLAR, AUSTEDO XR, Auvelity, UZEDY, COBENFY.
Industry payments across CA — which companies pay providers there.
